Kalvista Pharmaceuticals Inc (KALV) - News Archive

In an era marked by remarkable pharmaceutical breakthroughs, KalVista Pharmaceuticals, Inc. has recently highlighted the significant patient satisfaction associated with EKTERLY (sebetralstat), the first and only oral o...

CSIMarket.com KalVista Pharmaceuticals, Inc. has recently provided significant updates on its investigational drug, EKTERLY (sebetralstat), a novel oral on-demand treatment for hereditary angioedema (HAE). The recent pr...

In a world where pharmaceutical breakthroughs can change the lives of thousands, few stories exemplify the triumphs and tribulations of drug development like that of KalVista Pharmaceuticals, Inc. (Nasdaq: KALV). Recent...

KalVista Pharmaceuticals Unveils New Sebetralstat Data at AAAAI WAO 2025 Joint Congress: Promising Advances in Treating Hereditary Angioedema CAMBRIDGE, Mass. & SALISBURY, England KalVista Pharmaceuticals, Inc. (NASDAQ:...

KalVista Pharmaceuticals Announces Strategic Expansion with Key Inducement Grants KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a prominent name in the biopharmaceutical industry, recently fortified its team by grantin...

In the ever-competitive pharmaceutical landscape, the ability to deliver promising data at industry conferences can be a pivotal factor for companies striving to boost investor confidence and market presence. KalVista P...

In a recent announcement, KalVista Pharmaceuticals, based in Cambridge, Massachusetts, and Salisbury, England, disclosed it has granted stock options to incentivize new hires as part of its strategy to attract talented...

KalVista Pharmaceuticals Advances in Hereditary Angioedema Treatment Amidst Competitive Challenges KalVista Pharmaceuticals, Inc. a biomedical firm with roots in Cambridge, Massachusetts, and Salisbury, England, has mad...

KalVista Pharmaceuticals: Milestones and Advancements in Hereditary Angioedema Treatment KalVista Pharmaceuticals, Inc. based in Cambridge, Massachusetts and Salisbury, England, has recently delivered comprehensive upda...

KalVista Pharmaceuticals: A Strategic Move in the Market Amidst Financial Challenges CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) is making waves in the biotech landscape with it...

In a strategic move to finance its upcoming product launch, KalVista Pharmaceuticals, Inc. has closed a significant synthetic royalty financing agreement with DRI Healthcare Trust. This agreement, totaling up to $179 mi...

Recent developments in the management of hereditary angioedema (HAE) have seen the emergence of sebetralstat as a promising treatment option. KalVista Pharmaceuticals presented compelling data at the HAEi Global Angioed...

KalVista Pharmaceuticals Unveils Promising Sebetralstat Data at 2024 HAEi Global Angioedema Forum CAMBRIDGE, Mass. & SALISBURY, England KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has garnered significant attention fo...

In a significant advancement for the treatment of hereditary angioedema (HAE), KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has presented compelling data on its investigational drug, sebetralstat. The results highlight...

KalVista Pharmaceuticals Pursues Global Expansion for Sebetralstat in Treating Hereditary Angioedema KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), headquartered in Cambridge, Massachusetts, has taken a significant step...

: KalVista Pharmaceuticals, Inc. has presented new data on sebetralstat at the Bradykinin Symposium 2024, detailing findings from multiple phases of clinical trials. This article summarizes the key outcomes related to e...

KalVista Pharmaceuticals, Inc. has recently published its operational update and financial results for the first fiscal quarter ended July 31, 2024. Disclosing strategic advancements in their business, the company highl...

KalVista Pharmaceuticals, Inc. headquartered in Cambridge, Massachusetts, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat. This invest...

KalVista Pharmaceuticals Spearheads Breakthrough Research at 2024 Bradykinin Symposium in Berlin CAMBRIDGE, Mass. & SALISBURY, England Setting a notable milestone in its research trajectory, KalVista Pharmaceuticals, In...

In this eminent age of scientific inquiry and burgeoning pharmacology, it becomes exceedingly paramount to document with scholarly precision the latest developments that burgeon forth from the hallowed halls of medical...